Mesothelioma Clinical Trials and Treatments

Mesothelioma is a rare and aggressive cancer originating from mesothelial cells, the specialized cells lining the pleura (lungs), peritoneum (abdomen), pericardium (heart), and tunica vaginalis (testes). Approximately 80% of cases are pleural mesothelioma, and the vast majority are linked to asbestos exposure. Asbestos fibers, when inhaled or ingested, become lodged in tissue and cause chronic inflammation that over decades can trigger malignant transformation.

The most common symptoms of Mesothelioma include Shortness of breath and chest pain (pleural type), Abdominal swelling and pain (peritoneal type), Unexplained weight loss, Fatigue and muscle weakness, Persistent dry cough, among others. About 3,000 new cases per year in the U.S.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Mesothelioma from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Mesothelioma research is moving forward on multiple promising fronts, with active trials evaluating innovative immunotherapy combinations, targeted therapies for specific molecular subtypes like BAP1-altered tumors, gene therapy approaches, and novel surgical techniques that may improve outcomes. Because mesothelioma is complex and rapidly evolving, seeking care at a National Cancer Institute-designated comprehensive cancer center with mesothelioma expertise from the outset can significantly impact your treatment options and access to cutting-edge trials.

Yes. As of October 14, 2026, 4 FDA-approved medicines have a current label that names Mesothelioma: Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph); Opdivo (nivolumab); Pemfexy (pemetrexed); and Yervoy (ipilimumab). Corticosteroids and immune globulins count once each.

Mesothelioma arises from acquired (somatic) genetic changes in the affected cells, commonly involving BAP1, rather than from an inherited variant. About 70 to 80% of cases follow asbestos exposure; a germline BAP1 variant (BAP1 tumor predisposition syndrome) explains a small hereditary subset. About 3,000 new cases per year in the U.S.

For Mesothelioma the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for BAP1. About 70 to 80% of cases follow asbestos exposure; a germline BAP1 variant (BAP1 tumor predisposition syndrome) explains a small hereditary subset.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Mesothelioma clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Mesothelioma clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.